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Crohn's disease is a lifelong disease arising from an interaction between genetic and environmental factors, but 
observed predominantly in developed countries of the world. The precise aetiology is unknown and therefore a 
causal therapy is not yet available. Within Europe there is a distinct North-South gradient, but the incidence 
appears to have increased in Southern countries in recent years.1 Many patients live with a considerable 
symptom burden despite medical treatment in the hope that the aetiology of the disease will shortly be revealed 
and curative therapies emerge. Since it is uncertain that the precise pathogenesis of Crohn's disease will be 
revealed anytime soon, clinicians have to advise patients on the basis of information available today rather than 
an unknown future. Despite a multiplicity of randomised trials there will always be many questions that can only 
be answered by the exercise of judgement and opinion. This leads to differences in practice between clinicians, 
which may be brought into sharp relief by differences in emphasis between countries. 
The Consensus endeavours to address these differences. The Consensus is not meant to supersede the guidelines 
of different countries (such as those from the UK,2 Germany,3 or France), which reach broadly the same 
conclusions since they are, after all, based on the same evidence. Rather, the aim of the Consensus is to promote 
a European perspective on the management of Crohn's disease and its dilemmas. Since the development of 
guidelines is an expensive and time-consuming process, it may help to avoid duplication of effort in the future. A 
Consensus is also considered important because an increasing number of therapeutic trials are based in Europe, 
especially in eastern European countries where practice guidelines have yet to be published. 
This document is based on the European consensus on the diagnosis and management of Crohn's disease, 
reached by the European Crohn's and Colitis Organisation (ECCO) at a meeting held in Prague on 24th 
September 2004.4,5 On 18th October 2008, in Vienna, the guidelines were revised at a meeting of the ECCO 
guidelines task force. ECCO is a forum for specialists in inflammatory bowel disease from 32 European 
countries. It was established in 2000 with the common purpose of promoting European views, clinical trials and 
specialist training in inflammatory bowel disease. The Consensus is grouped into three parts: definitions and 
diagnosis; current management; and management of special situations. This first section concerns aims and 
methods of the Consensus, as well as diagnosis, pathology, and classification of Crohn's disease. The second 
section on Current Management includes treatment of active disease, maintenance of medically-induced 
remission and surgery of Crohn's disease. The third section on Special Situations in Crohn's disease includes 
post-operative recurrence, fistulating disease, paediatrics, pregnancy, psychosomatics, extraintest-inal 
manifestations and alternative therapy. 
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The strategy to reach the Consensus on the guideline revisions involved six steps: 
1.  Guideline statements of 2004 were analysed systematically by the chairs of the working parties. Guideline 
statements selected for change and questions unresolved by the 2004 ECCO guidelines were distributed to the 
working party members. Participants were asked to answer the questions based on their experience as well as 
evidence from the literature (Delphi procedure).6 
2.  In parallel, the working parties performed a systematic literature search of their topic with the appropriate key 
words using Medline/Pubmed and the Cochrane database, as well as their own files. The evidence level (EL) was 
graded (Table 1.1) according to the Oxford Centre for Evidence-Based Medicine.7 
3.  Provisional guideline statements on their topic were then written by the chairmen, posted on a weblog. 
Discussions and exchange of the literature evidence among the working party members was then performed on 
the weblog. This process was supervised by Axel Dignass and Gert Van Assche. 
4.  On September 30 all working party chairs submitted the proposed changes to the 2004 guidelines to Gert Van 
Assche and Axel Dignass, who compiled them in a working document. 
5.  The working parties then met in Vienna on the 18th October 2008 to agree on the statements. Technically this 
was done by projecting the statements and revising them on screen until a consensus was reached. Consensus 
was defined as agreement by >80% of participants, termed a Consensus Statement and numbered for 
convenience in the document. Each recommendation was graded (RG) according to the Oxford Centre for 
Evidence Based Medicine,7 based on the level of evidence (Table 1.1). 
6.  The final document on each topic was written by the chairmen in conjunction with their working party. 
Consensus guideline statements in bold are followed by comments on the evidence and opinion. Statements are 
intended to be read in context with qualifying comments and not read in isolation. The final text was edited for 
consistency of style by A. Dignass, J Lindsay, SPL Travis and G Van Assche before being circulated and 
approved by the participants. In some areas the level of evidence is generally low, which reflects the paucity of 
randomised controlled trials. Consequently expert opinion is included where appropriate. 
 
1.1. Definitions 
Common agreement was reached about frequently used terms. While the significance of some terms (such as 
'early-' or 'pattern of relapse') is undetermined, such terms reflect clinical decision making (such as when to start 
immunomodulators). The arbitrariness of some of the definitions is recognized, but the Consensus considers it 
useful to agree to the terminology. 
 
1.1.1.  Active disease 
For the purposes of this Consensus, clinical disease activity is grouped into mild, moderate and severe (Table 
1.2). These are not precisely defined entities. Most clinical trials in patients with active Crohn's disease recruit 
patients with a Crohn's Disease Activity Index (CDAI) of >220. The fallibility of this threshold is illustrated by 
the high placebo response in recent trials of biological therapy8 and the trend is now to use a CRP of >10 mg/L 
in conjunction with the CDAI. Remission (see below) is widely accepted as a CDAI of <150 and response is 
increasingly defined as a decrease in CDAI by ≥100 points. It would make sense to define disease activity in 
groups of 100 points, at least until a sensitive, responsive and validated index superior to the CDAI is 
developed.9 This is an inconsistency that needs to be resolved, but until it can be modeled on clinical trial data 
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Table 1.1     Levels of evidence and grades of recommendation based on the Oxford Centre for Evidence Based 
Medicine. For details see http://www.cebm.net/levels_of_evidence.asp#refs. 
Level Individual study Technique 
1a Systematic review (SR) with homogeneity of Level 1 
diagnostic studies 
Systematic review (SR) with homogeneity of randomised 
controlled trials (RCTs) 
1b Validating cohort study with good reference standards Individual RCT (with narrow Confidence Interval) 
1c Specificity is so high that a positive result rules in the 
diagnosis ("SpPin") or sensitivity is so high that a 
negative result rules out the diagnosis ("SnNout") 
All or none 
2a SR with homogeneity of level >2 diagnostic studies SR (with homogeneity ) of cohort studies 
2b Exploratory cohort study with good reference standards Individual cohort study (including low quality RCT; e.g., 
<80% follow up) 
2c  "Outcomes" research; ecological studies 
3a SR with homogeneity of 3b and better studies SR with homogeneity of case-control studies 
3b Non-consecutive study; or without consistently applied 
reference standards 
Individual case-control study 
4 Case-control study, poor or non-independent reference 
standard 
Case-series (and poor quality cohort and case-control 
studies) 
5 Expert opinion without explicit critical appraisal, or 
based on physiology, bench research or "first principles" 
Expert opinion without explicit critical appraisal, or 
based on  
physiology, bench research or "first principles" 
Grades of recommendation 
A Consistent level 1 studies 
B Consistent level 2 or 3 studies or extrapolations from level 1 studies 
C Level 4 studies or extrapolations from level 2 or 3 studies 
D Level 5 evidence or troublingly inconsistent or inconclusive studies of any level 
 
Table 1.2     Grading of disease activity in Crohn's disease. 
Mild Moderate Severe 
Equivalent to a CDAI of 150-220 
e.g. Ambulatory, eating and drinking, 
<10% weight loss. 
Equivalent to a CDAI of >450 
e.g. Cachexia (BMI <18 kg m-2), or 
evidence of obstruction or abscess. 
No features of obstruction, fever, 
dehydration, abdominal mass, or 
tenderness. CRP usually increased 
above the upper limit of normal. 
Equivalent to a CDAI of 220-450 
e.g. Intermittent vomiting, or weight 
loss >10%. Treatment for mild disease 
ineffective, or tender mass. No overt 
obstruction. CRP elevated above the 
upper limit of normal. 
Persistent symptoms despite intensive 
treatment. CRP increased. 
Note: symptoms of obstruction are not always related to inflammatory activity and should be investigated with additional imaging as outlined 
further in the paper. 
 
1.1.2.  Remission 
The criterion used in the majority of clinical trials when selecting Crohn's disease patients in clinical remission is 
a CDAI of <150.10 This has become the customary definition and is accepted for the purposes of evaluating the 
literature and clinical trials for as long as the CDAI remains the principal index for evaluating outcome in trials 
of Crohn's disease. In several studies, a biological index of Brignola of <10011,12 was also a requirement. This has 
the advantage of objectivity, but is not used in clinical practice. In keeping with the views of the International 
Organisation for the study of Inflammatory Bowel Disease,  ECCO believes that studies evaluating the 
maintenance of remission in Crohn's disease should last at least 12 months.5,10 
 
1.1.3.  Response 
Response should be defined by a ∆CDAI of ≥100 points, although in some studies, including those initially 
evaluating the effectiveness of inf liximab, a lesser end point of response with a reduction in CDAI by ≥70 
points13'14 was used. 
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1.1.4.  Relapse 
The term relapse is used to define a flare of symptoms in a patient with established CD who is in clinical 
remission, either spontaneously or after medical treatment. Relapse is preferably confirmed by laboratory 
parameters, imaging or endoscopy in clinical practice. For the purposes of clinical trials a CDAI of >150 with an 
increase of more than 70 points has been proposed.10 However, if a therapeutic response is defined as a decrease 
in CDAI by ≥100 points, then the definition would more rationally be a CDAI of >150 with an increase of 100 
points from baseline. There is no international agreement on this, but future trials on Crohn's disease should take 
this into account. Other definitions (including CDAI>150, or a CDAI>250, or an increase of 50 points if the 
baseline was between 150 and 250) are considered less acceptable. 
 
1.1.5. Early relapse 
An arbitrary, but clinically relevant period of <3 months after achieving remission on previous therapy defines 
early relapse. The therapeutic significance needs to be defined. 
 
1.1.6.  Pattern of relapse 
Relapse may be infrequent (≤1/yr), frequent (≥2 relapses/ yr), or continuous (persistent symptoms of active CD 
without a period of remission). Although the terms are arbitrary, they are considered clinically relevant. The 
prognostic significance needs to be determined. 
The term 'chronic active disease' has been used in the past to define a patient who is dependent on, refractory to, 
or intolerant of steroids, or who has disease activity despite immunomodulators. Since this term is ambiguous it 
is best avoided. Instead, arbitrary, but more precise definitions are preferred, including steroid-refractory or 
steroid-dependence. 
 
1.1.7.  Steroid-refractory disease 
Patients who have active disease despite prednisolone of up to 0.75 mg/kg/day over a period of 4 weeks. 
 
1.1.8.  Steroid-dependent disease 
Patients who are either 
i) unable to reduce steroids below the equivalent of prednisolone 10 mg/day (or budesonide below 3 mg/day) 
within 3 months of starting steroids, without recurrent active disease, or 
ii) who have a relapse within 3 months of stopping steroids. 
The assessment of steroid-refractoriness or -dependence should be made after careful exclusion of disease-
specific complications. 
This definition of steroid-dependence requires that the total duration of steroids does not exceed 3 months before 
a threshold equivalent to prednisolone 10 mg/day is reached. Patients are still considered steroid-dependent if 
they relapse within 3 months of stopping steroids. Although these limits are arbitrary, they serve as guidance for 
clinical practice and may be used for uniformity in clinical trials. The aim should be to withdraw steroids 
completely. 
 
1.1.9.  Recurrence 
The term recurrence is best used to define the reappearance of lesions after surgical resection (while relapse 
refers to the reappearance of symptoms, above). 
 
1.1.10.  Morphologic recurrence 
The appearance of new CD lesions after complete resection of macroscopic disease, usually in the neo-terminal 
ileum and/ or at the anastomosis, detected by endoscopy, radiology or surgery.15,16 Endoscopic recurrence is 
currently evaluated and graded according to the criteria of Rutgeerts et al. (0: no lesions; 1: less than 5 aphthous 
lesions; 2: more than 5 aphthous lesions with normal mucosa between the lesions, or skip areas of larger lesions, 
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or lesions confined to the ileocolonic anastomotic lining (<1 cm); 3: diffuse aphthous ileitis with diffusely 
inflamed mucosa; and 4: diffuse ileal inflammation with larger ulcers, nodules, or narrowing. Hyperaemia and 
oedema alone are not considered as signs of recurrence).15 Also, all post-operative changes visualized by 
ultrasound or CT/MRI are not specifically indicating disease recurrence (also see Section 2.3.1). 
 
1.1.11.  Clinical recurrence 
The appearance of CD symptoms after complete resection of macroscopic disease, provided (for the purposes of 
clinical trials) that recurrence of lesions is confirmed.16 Symptoms suggestive of CD can be caused by motility 
disturbances or bile malabsorption, which underscores the need for confirmation of inflammatory, penetrating or 
fibrotic lesions.17 
 
1.1.12.  Localised disease 
Intestinal Crohn's disease affecting <30 cm in extent. This usually applies to an ileocaecal location (<30 cm 
ileum ± right colon), but could apply to isolated colonic disease, or conceivably to proximal small intestinal 
disease. 
 
1.1.13.  Extensive Crohn's disease 
Intestinal Crohn's disease affecting >100 cm in extent whatever the location. This applies to the sum of 
inflammation in discontinuous segments. While there is clearly a 'grey area' of disease extent (between 30 and 
100 cm) and the length is arbitrary, this definition of extensive disease recognises the greater inflammatory 
burden and implications for medical and surgical decision making with this extent of disease. 
 
1.1.14.  New patient 
A patient with active CD presenting at, or shortly after diagnosis, with no previous therapy for CD. 
 
1.1.15.  Alternative therapy 
One that is used in place of conventional medicine. 
 
1.1.16.  Complementary therapies 
Similar treatments used alongside conventional medicine (see Section 1.1.15 for comment). 
 
1.1.17.  Expert opinion 
The term 'expert' is used here to refer to the opinion of the specialists in inflammatory bowel disease representing 
multiple disciplines from 22 European countries who contributed to the ECCO Consensus. In some sections 
opinions from individual members of other expert bodies were obtained, including individuals of the European 
Society of Pathology (ESP) working group on Digestive Diseases, or the European Society of Gastrointestinal 
and Abdominal Radiology (ESGAR). 
 
2. Clinical diagnosis and imaging 
Principal changes with respect to the 2004 ECCO guidelines. 
•  MR or CT enterograpy/enteroclysis is an imaging technique with the highest diagnostic accuracy for the 
detection of intestinal involvement of CD including extramural complications [statements 2F and 2G]. 
•  Small bowel capsule endoscopy should be reserved for those patients with a high clinical suspicion of CD 
despite negative investigation by ileocolonoscopy and other imaging techniques [statement 2I]. 
CD most frequently presents in late adolescence or early adulthood and is equally distributed between the 
sexes.18 
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Symptoms at presentation vary depending on the location, behaviour and severity of disease, as well as 
extraintestinal manifestations and medication. The aim is to establish the diagnosis and distribution of disease by 
appropriate techniques, because this influences the choice of treatment. Both gastroenterologists and radiologists 
have been involved in the development of the guidance on appropriate radiological techniques for patients with 
CD. 
 
2.1.  Clinical features of CD 
ECCO statement 2A 
Symptoms of CD are heterogeneous, but commonly include diarrhoea for more than 6weeks, abdominal pain 
and/or weight loss. These symptoms should raise the suspicion of CD, especially in patients at a young age. 
Systemic symptoms of malaise, anorexia, or fever are common [EL5, RG D]. 
Chronic diarrhoea is the most common presenting symptom19 a definition of a decrease in faecal consistency for 
more than 6 weeks may be adequate to differentiate this from self limited, infectious diarrhoea.20 More acute 
presentations may occur, and acute terminal ileal Crohn's disease may be mistaken for acute appendicitis. 
Chronic non-specific symptoms mimicking irritable bowel syndrome (IBS), unexplained anaemia and growth 
failure in children should also be considered to avoid delayed diagnosis.21,22 Abdominal pain and weight loss are 
seen in about 70% and 60% respectively of patients before diagnosis. Although the irritable bowel syndrome is 
more common than CD, associated systemic symptoms, blood in stools and weight loss, should always trigger 
further investigations. Blood and/or mucus in the stool may be seen in up to 40% to 50% of patients with Crohn's 
colitis, but less frequently than in ulcerative colitis (UC).23 Patients may present with extraintestinal 
manifestations of Crohn's disease before the gastrointestinal symptoms become prominent. Abnormalities of the 
musculoskeletal system are the most common extraintestinal manifestations of IBD, encompassing peripheral 
and axial joints.24 Extraintestinal manifestations are most common when CD affects the colon. Perianal fistulas 
are present in 10% of patients at the time of diagnosis,25 and may be the presenting complaint. 
 
2.2.  Diagnosis 
ECCO statement 2B 
A single gold standard for the diagnosis of CD is not available. The diagnosis is confirmed by clinical evaluation 
and a combination of endoscopic, histological, radiological, and/or biochemical investigations. Genetic testing is 
currently not recommended for routine diagnosis or management of CD. [EL5, RG D]. 
CD is a heterogeneous entity comprising a variety of complex phenotypes in terms of age of onset, disease 
location and disease behaviour.26 As there is no single way to diagnose CD, Lennard-Jones et al. have defined 
macroscopic and microscopic criteria to establish the diagnosis. The macroscopic diagnostic tools include 
physical examination, endoscopy, radiology, and examination of an operative specimen. Microscopic features 
can be only partly assessed on mucosal biopsy, but completely assessed on an operative specimen. The diagnosis 
depends on the finding of discontinuous and often granulomatous intestinal inflammation.23 The current view is 
that the diagnosis is established by a non-strictly defined combination of clinical presentation, endoscopic 
appearance, radiology, histology, surgical findings and, more recently, serology. This still results in diagnostic 
obstacles. A change in diagnosis to UC during the first year occurs in about 5% of cases. IBD restricted to the 
colon that cannot be allocated to the CD or UC category is best termed colitis unclassified and the term 
indeterminate colitis confined to operative specimens as originally described.27 The indiscriminate use of the 
term indeterminate colitis to cover all cases of diagnostic uncertainty is confusing in the literature and imprecise 
in practice. 
 
2.2.1. History and examination 
ECCO statement 2C 
A full history should include detailed questioning about the onset of symptoms, recent travel, food intolerances, 
medication (including antibiotics and non-steroidal anti-inflammatory drugs), and history of appendicectomy 
[EL5, RG D]· Particular attention should be paid to well proven risk factors including smoking, family history, 
and recent infectious gastroenteritis [EL1b RGB]. 
ECCO statement 2D 
Careful questioning about nocturnal symptoms, features of extraintestinal manifestations involving the mouth, 
skin, eye, or joints, episodes of perianal abscess, or anal fissure is appropriate. General examination includes 
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general well-being, pulse rate, blood pressure, temperature, abdominal tenderness or distension, palpable masses, 
perineal and oral inspection, and rectal digital examination. Measurement of body weight and calculation of 
body mass index are recommended [EL5, RG D]. 
Smoking, prior appendicectomy, and a family history of IBD have been reproduced as risk factors for the onset 
of CD.28,29 Infectious gastroenteritis is followed by an increased risk (four-fold) of developing CD especially in 
the following year, although the absolute risk is low.30 Retrospective studies on non-steroidal anti-inflammatory 
drugs as a risk factor for CD are less consistent.31 
 
2.2.2. Initial laboratory investigations 
ECCO statement 2E 
Check for signs of acute and/or chronic inflammatory response, anaemia, fluid depletion, and signs of 
malnutrition or malabsorption [EL5, RG D]· Initial laboratory investigations should include CRP [EL2, RG B], 
and full blood count [EL5, RG D]· If C-reactive protein is not available, then measurement of the erythrocyte 
sedimentation rate (ESR) may be used [EL5, RG D]· Other biochemical markers may also be used to identify gut 
inflammation, in particular faecal calprotectin. [EL1b RG B] Microbiological testing for infectious diarrhoea 
including Clostridium difficile toxin is recommended [EL2, RG B]. Additional stool tests may be needed for 
patients who have travelled abroad [EL5, RG D]. 
Anaemia and thrombocytosis represent the most common changes in the full blood count of patients with CD. 
The C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) are standard laboratory surrogates of the 
acute phase response to inflammation. The CRP broadly correlates with disease activity of CD assessed by 
standard indices and indicates serial changes in inflammatory activity because of its short half life of 19 h.29,32-34 
The ESR less accurately measures intestinal inflammation in CD by reflecting changes of plasma protein 
concentration and packed cell volume. The ESR increases with disease activity, but correlates better with colonic 
rather than ileal disease.35 Estimation of faecal markers of inflammation have been shown to correlate well with 
intestinal inflammation, particularly faecal calprotectin, which has a positive predictive value of 85-90% in 
distinguishing IBD from irritable bowel syndrome36-40 and lactoferrin.36,40 However, while these markers have 
been tested in relatively small populations as diagnostic markers, most evidence comes from studies performed 
on patients with CD predicting relapse rather than in initial diagnosis. Improved diagnostic accuracy may come 
from newer tests including faecal S100A12.41,42 None of the above parameters is specific enough to permit 
differentiation from UC or enteric infection. Evidence for a pathophysiological role of certain strains of luminal 
bacteria in genetically susceptible hosts in CD comes from animal models and studies on innate immunity. None 
yet have a diagnostic role. The value of routine stool examination in patients with suspected CD or exacerbations 
of disease arises from both the differential diagnosis and high concordance with enteric infections such as C. 
difficile.43 
Serologic testing currently available may be used as an adjunct to diagnosis, but the accuracy of the best of the 
available tests (ASCA and ANCA) is such that they are unlikely to be useful in routine diagnosis, and are 
ineffective at differentiating colonic Crohn's disease from ulcerative colitis.44,45 Other serological markers such 
as anti-OmpC and CBirl have not yet been shown to help in differentiating CD from UC.34,46-48 Despite the 
advances in the field of Crohn's disease genetics there are currently no genetic tests which are recommended 
routinely for diagnosis. 
 
2.2.3. Procedures recommended to establish the diagnosis 
ECCO statement 2F 
For suspected CD, ileocolonoscopy and biopsies from the terminal ileum as well as each colonic segment to look 
for microscopic evidence of CD are first line procedures to establish the diagnosis [EL1b, RG A]. Irrespective of 
the findings at ileocolonoscopy, further investigation is recommended to examine the location and extent of any 
CD in the upper gastrointestinal tract or small bowel [EL5, RG D]. 
Colonoscopy with multiple biopsy specimens is well established as the first line procedure for diagnosing 
colitis.49 Ileoscopy with biopsy can be achieved with practice in at least 85% of colonoscopies and increases the 
diagnostic yield of CD in patients presenting with symptoms of IBD.49-52 The most useful endoscopic features of 
CD are discontinuous involvement, anal lesions and cobble stoning. Colonoscopy assesses the anatomical 
severity of CD colitis with a high specificity. Anatomical criteria of severity are defined as deep ulcerations 
eroding the muscle layer, or mucosal detachments or ulcerations limited to the submucosa but extending to more 
than one third of a defined colonic segment (right, transverse, and left colon).53 When there is severe, active 
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disease, the value of full colonoscopy is limited by a higher risk of bowel perforation and diagnostic errors are 
more frequent. In these circumstances initial flexible sigmoidoscopy is safer and ileocolonoscopy postponed 
until the clinical condition improves.54 The scoring of endoscopic disease activity in CD is reserved for clinical 
studies.10 Ileoscopy is superior for the diagnosis of CD of the terminal ileum55-57 when compared with radiology 
techniques, including MR and CT, specially for mild lesions. Capsule endoscopy and enteroscopy with biopsy 
by a push endoscope are safe and useful procedures for diagnosis of CD in selected patients with suggestive 
symptoms after failure of radiologic examinations.58 
A plain abdominal radiograph is valuable in the initial assessment of patients with suspected severe CD by 
providing evidence of small bowel or colonic dilatation, calcified calculi, sacroiliitis, or the impression of a mass 
in the right iliac fossa. It is not a diagnostic test for CD. 
 
2.3. Extent of disease 
2.3.1. Procedures recommended for establishing the extent of CD 
CD may affect the ileum out of reach of an endoscope, or involve more proximal small bowel (10% of patients.) 
Additionally, at the time of diagnosis 15.5% of patients have penetrating lesions (fistulas, phlegmons or 
abscesses).43 Endoscopy and radiology are complementary techniques to define the site and extent of disease, so 
that optimal therapy can be planned.59-61 
ECCO statement 2G 
MR and CT enterography or enteroclysis is an imaging technique with the highest diagnostic accuracy for the 
detection of intestinal involvement and penetrating lesions in CD [EL1b, RGB]. Radiation exposure should be 
considered when selecting techniques. Because of the lower sensitivity of barium studies, alternative techniques 
are preferred if available. Transabdominal ultrasonography is a useful additional technique for assessing bowel 
inflammation. 
CT and MR are the current standards for assessing the small intestine. Both techniques can establish disease 
extension and activity based on wall thickness and increased intravenous contrast enhancement. The magnitude 
of these changes, along with presence of edema and ulcerations allow categorization of disease severity.61,62 Both 
CT and MR are also the most accurate techniques to detect presence of extraluminal complications. Fluoroscopic 
examinations have a considerably lower sensitivity for the detection of small bowel and extraluminal lesions 
compared to CT or MR.64-66 
CT and MR have a similar diagnostic accuracy for the detection of small intestine inflammatory lesions.55,67 CT 
has greater availability and is less time-consuming than MR. The radiation burden from fluoroscopy and CT is 
appreciable.68 Considering that these examinations need to be repeated over time and the young age of the IBD 
population, radiation exposure resulting from CT examination may entail an increased risk of cancer. Therefore, 
MR should be considered where possible. 
CT and MR examinations of the small intestine require oral luminal contrast to achieve adequate distension.69 
Administration of luminal contrast by enteroclysis allows better small bowel distention than simple oral 
ingestion. However, nasojejunal tube placement entails radiation exposure and produces discomfort. The only 
study comparing both modalities in MR examinations concluded that bowel distension was inferior in MR 
follow-through, but diagnostic accuracy was similar using both methods.69 Likewise, oral CT enterography has 
similar accuracy for enabling the detection of active Crohn's disease in comparison with CT enteroclysis with 
nasojejunal tube.62 Oral ingestion of the luminal contrast provides adequate distension of the ileum. Enteroclysis 
may be necessary in selected cases in which upper CD lesions are suspected and adequate distention is not 
achieved with oral administration of the luminal contrast. 
Transabdomina ultrasound (US) represents another non-ionizing imaging technique which may provide 
information about disease activity, in particular for CD limited to the ileum.60 Use of contrast-enhanced 
abdominal US70 and Doppler US71,72 may increase the sensitivity and specificity of this technique for the 
detection of disease activity. However, difficulty of visualization of deep bowel segments and high interobserver 
variability represent significant drawbacks. Nevertheless, in situations in which an overview of the inflammatory 
lesions is desirable, such as initial or emergency patient assessment, transabdominal US is a valuable, widely 
available, and inexpensive tool to judge site and extent of inflammation and possible complications. 
Leucocyte scintigraphy is safe, non-invasive, and potentially permits assessment of the presence, extent, and 
activity of inflammation but radiation exposure and limited sensitivity, especially in patients under steroid 
treatment,73 are leading to a reduced usage of this technique. 
Evidence of the diagnostic yield of the above imaging techniques for assessment of colonic CD is growing, and 
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seems to be highly dependent on technical details. MR has a high sensitivity and specificity for colonic 
inflammatory lesions when dark lumen (water enema) contrast and intravenous contrast are used, but diagnostic 
accuracy is considerably lower if these are not used.64,74,75 The present data indicate that faecal tagging using 
barium instead of bowel cleansing is not suitable for MR colonography in CD.76 Two studies evaluating the 
value of CT for the characterization of inflammatory lesions in the colon suggests a limited sensitivity of CT.77,78 
A single study also suggests a high sensitivity and specificity of water enema US for the evaluation of colonic 
CD.79 
Small bowel capsule endoscopy (SBCE) has a higher sensitivity compared to MR or CT for the diagnosis of 
small bowel lesions, particularly for the detection of superficial mucosal lesions.57,80 SBCE can be used as a first 
line test after exclusion of significant stenosis using a patency capsule or as second line in patients in whom the 
clinical suspicion for CD remains high despite negative evaluations with ileocolonoscopy and radiology. 
Double balloon enteroscopy (DBE) has also a higher sensitivity for the detection of small bowel lesions than 
radiological techniques.81 However, completeness of small bowel assessment is limited by the severity of 
inflammatory lesions in proximal segments, and is associated to higher risks than SBCE. DBE should be used 
when tissue samples for pathological examinations are needed and when therapeutic maneuvers are required. 
 
2.3.2. Procedures recommended for establishing the extent of stricturing CD 
The procedures above (Section 2.3.1) apply to stricturing disease, but obstructive symptoms create their own 
challenge. The most reliable criterion for defining a stricture is a localised, persistent narrowing, whose 
functional effects may be judged from pre-stenotic dilatation.26 
For the detection of stenosis in the colon and distal ileum ileocolonoscopy is recommended as the first choice, 
allowing tissue sampling for pathologic diagnosis. Complementary radiologic techniques to rule out additional 
stenotic lesions are necessary when the lesion is impassable with an endoscope. 
Plain film radiography may identify small bowel obstruction but cannot depict the cause, making additional 
diagnostic workout based on MR or CT necessary. Both techniques are superior to conventional barium studies 
for detection of stenotic lesions.63,81,82 Direct comparison of CT and MR for the diagnosis of a variety of small 
intestine lesions including IBD, demonstrates a high sensitivity and specificity, similar in both techniques51. 
Comparison of enteroclysis and oral contrast administration on CT and MR examinations resulted in coincident 
results, showing a superior bowel distension when enteroclysis was used, but a similar diagnostic accuracy for 
the detection of stenotic lesions,62,69,83 although enteroclysis may be superior for the demonstration of low grade 
stenosis.84 
US is helpful in detecting pre-stenotic dilatation in small bowel strictures in severe cases that are candidates for 
surgery.85,86 If colonoscopy is incomplete because of stricture, then MR or CT colonography (CT) can be used to 
evaluate colonic inflammatory lesions in the segments not explored by endoscopy. Differentiation between 
inflammatory and fibrostenotic strictures is crucial to the choice of therapy, but the diagnostic value of current 
techniques for making this distinction has not been adequately evaluated. CT and MRI can detect disease activity 
at a stricture based on the presence of edema, mucosal ulceration and contrast enhancement.85,87 Contrast-
enhanced Doppler US may also be valuable in determining disease activity within strictures.87-89 However, the 
prognostic value of all these findings for response to medical treatment is still under investigation. 
 
2.3.3.  Procedures recommended for detecting extramural complications 
ECCO statement 2H 
CT and MR are the recommended techniques for detection of extramural complications of CD [EL1b, RGA]. 
Transabdominal ultrasonography may also be used, but diagnostic accuracy is lower [EL2b, RGB]. 
Both CT and MR are highly accurate for the detection of abscesses, fistulae and inflammatory conglomerates in 
CD.62,63,89,90 Barium examinations have a considerably lower sensitivity compared to CT and MR for the 
detection of fistulas between the intestine and other organs, while for identification of enteroenteric fistulae 
barium studies have a similar sensitivity to CT and MR66 The use of CT with positive oral contrast may be 
superior to MR for the distinction between an abscess and distended bowel loops within inflammatory 
conglomerates. Fistula formation around the affected or strictured bowel segment does provide a typical image 
when applying the MRE: the star-sing.91,92 
US is an operator-dependent, but readily available, diagnostic tool for the diagnosis of extramural complications 
in CD. For the detection of fistulas and abscesses, respective sensitivities of 87% and 100% have been 
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reported.93 However diagnostic accuracy is higher for CT because of false positive results in US studies.94 
 
2.3.4.  Role of gastroduodenoscopy and biopsy in a patient with CD 
CD involving the upper gastrointestinal tract is almost invariably accompanied by small or large bowel 
involvement.95-97 Gastric biopsies may be useful when a patient has colitis unclassified, as focal active gastritis in 
the absence of ulceration may be a feature of CD (Section 3.2.5). 
 
2.3.5. Role of small bowel capsule endoscopy (SBCE) and double balloon enteroscopy (DBE) in suspected 
or proven CD 
ECCO statement 2I  
Small bowel capsule endoscopy (SBCE) should be reserved for patients in whom the clinical suspicion for CD 
remains high despite negative evaluations with ileocolonoscopy and radiological examinations (SBE/SBFT or 
CTE or MRE) [EL2; RG B]. 
Double balloon enteroscopy (DBE) should be reserved for specific situations in which biopsy samples from 
suspected involved areas are important for diagnosis or in which a dilatation of strictures is reasonable [EL5, RG 
D]. 
SBCE is a novel method of directly visualising small bowel lesions in patients with IBD that may be missed by 
traditional endoscopic or radiological procedures. SBCE is a sensitive tool to detect mucosal abnormalities in the 
small bowel. The diagnostic yield (prevalence of abnormal findings) of SBCE is superior to other modalities 
(SBE/SBFT and CT enteroclysis) for diagnosing small bowel CD.65,80,98-104 Contraindications for SBCE include 
gastrointestinal obstruction, strictures or fistulas, pacemakers or other implanted electromedical devices, and 
swallowing disorders.105 
In cases of suspected CD, SBCE is likely to be more sensitive than other imaging modalities for diagnosis of 
mucosal lesions indicative of small bowel CD. A normal SBCE examination has a very high negative predictive 
value, essentially ruling out small bowel CD. However, the use of SBCE in cases of suspicion of small bowel 
CD is limited by a lack of specificity. CD associated lesions described by SBCE need more precise definition. 
Indeed, over 10% of healthy subjects demonstrate mucosal breaks and erosions in their SB. Thus, SBCE findings 
of mucosal lesions of the small bowel are not alone sufficient to establish a diagnosis of CD. 
For some authors, SBCE could be used as a first line test. They recommend to use patency capsule either/or 
small bowel imaging before SBCE only if there is a suspicion of obstruction.106 Because of the high frequency of 
partial obstruction, others recommend performing small bowel imaging (SBE/SBFT or CTE or MRE) 
systematically in patients with suspected CD.107 Then, SBCE would be reserved for patients in whom the clinical 
suspicion for CD remains high despite negative evaluations with ileocolonoscopy and radiological examinations. 
Large prospective studies are needed to position SBCE in a diagnostic algorithm for CD. 
Among patients with proven CD, SBCE could be used to determine the extent and severity of lesions, post-
operative recurrence and mucosal healing under therapies. In clinical practice, indications of SBCE are limited in 
patients with proven CD. It may be useful in the clinical setting of functional bowel disorders to assess whether 
inflammatory lesions are present. 
The major advantages of double balloon enteroscopy (DBE) compared with SBCE are its ability to obtain biopsy 
samples and perform therapeutic measures during the procedure. There are specific situations in patients with 
CD in which a DBE may be useful. 
In a recent study of a cohort of 40 patients with CD, DBE was found to be superior to small bowel follow-
through imaging or barium enteroclysis for detecting erosions and small ulcerations in the distal ileum.108 
Biopsies can be taken when SBCE shows unclear small intestinal lesions. However, this should be restricted to 
patients in which definitive verification of jejunal or ileal involvement would have therapeutic implications. 
The therapeutic potential of DBE has been demonstrated by reports of stricture dilatation and the retrieval of 
retained SBCE devices. 
Risks include those inherent to endoscopy. In addition, risks associated with prolonged sedation time have to be 
considered. Further, it seems to be likely that CD patients undergoing DBE may have an increased risk of 
perforation due to possible adhesions, mucosal damage by the underlying diseases or adhesions after surgery. 
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2.3.6. Procedures recommended preoperatively 
ECCO statement 2J 
Pre-operative imaging should follow strategies employed for the primary diagnosis of CD [EL5, RGD]. 
Small bowel mucosal lesions proximal to resection margins are found in about 65% of patients at the time of 
surgical intervention, most often undetected by radiography. These lesions do not, however, influence post-
operative outcome if they are not obliterating the lumen.109,110 
 
3. The histological diagnosis of Crohn's disease 
During the last 25 years, several elements have influenced the accuracy of the histological diagnosis of Crohn's 
disease. The widespread introduction of colonoscopy allowed the analysis of multiple mucosal biopsies from 
different segments of the colon and the ileum. The introduction of new therapies inducing healing of the mucosa 
has made the pathologist aware of the impact of treatment upon the diagnostic features. 
For this section articles reporting original research into the reproducibility, sensitivity or specificity of individual 
features for the histological diagnosis of Crohn's disease were sought from the literature using Medline and 
Pubmed. As further selection criteria, only those features which achieved moderate reproducibility judged by 
kappa value, or findings that were confirmed by subsequent studies, were considered. The purpose is to propose 
consensus guidelines for the histological diagnosis of Crohn's disease. The aspects discussed include: procedures 
required for a proper diagnosis; features which can be used for the analysis of endoscopic biopsies; features 
which can be used for the analysis of surgical samples; and diagnostic criteria. Questions that are addressed 
include: how many features should be present for a firm diagnosis? Is it useful to search for dysplasia? What is 
the role of histology in management? Which features if any, can be used for assessment of disease activity? 
 
3.1. Procedures for the diagnosis with endoscopic biopsies 
3.1.1.  Number of biopsies 
ECCO statement 3A 
For a  reliable diagnosis of Crohn's disease "multiple" biopsies from five sites around the colon  (including the 
rectum) and the ileum should be obtained. Multiple biopsies imply a minimum of two samples from each site 
[EL2, RGB]. 
ECCO statement 3B  
In patients with fulminant colitis, two samples from at least one site should be obtained [EL5, RGD]. 
For the initial diagnosis, analysis of a full colonoscopic biopsy series, rather than a single rectal biopsy, produces 
the most reliable diagnosis of Crohn's disease.111-119 Samples are preferably obtained both from areas which are 
involved by the disease and from uninvolved areas. During follow up examinations, a smaller number of biopsy 
samples may be useful to confirm the diagnosis. In post-surgical follow up, biopsies of the neo-terminal ileum 
are indicated when disease recurrence is suspected. Where patients have undergone ileal pouch-anal 
anastomosis, biopsies of the afferent limb are indicated when Crohn's disease is suspected. Multiple biopsies are 
indicated when the patient was investigated during screening for dysplasia (=intraepithelial neoplasia). 
 
3.1.2.  Handling of biopsies 
ECCO statement 3C 
The biopsy samples should be accompanied by clinical information including the age of the patient, duration of 
disease and duration and type of treatment [EL5, RG D]. 
ECCO statement 3D 
All tissue samples should be fixed immediately by immersion  in  buffered  formalin  or  an equivalent solution 
prior to transport [EL5, RG D]. 
ECCO statement 3E 
Since lesions may be mild or focal it is recommended that multiple sections from each sample are examined 
[EL2, RG B]. 
Biopsies from different regions should be handled in a way that the region of origin can be identified. This can 
be done by using different containers, multi-well cassettes or an acetate strip. Orientation of the samples using 
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filter paper (submucosal side down (before fixation, may yield better results, because it allowsa better 
assessment of architectural abnormalities [EL5, RG D]. The ideal number of sections to be examined in routine 
practice is not established, but numbers vary between 2 and 6 in different studies.118,119 The diagnostic yield 
increases when more sections are examined. It is not clear whether serial-sections or step-sections from different 
levels of the sample should be examined. In one comparative study of rectal biopsies, serial-sectioning increased 
the ability to detect focal abnormalities including granulomas compared to step-sectioning. Confirmation of this 
finding is needed.120 In routine practice, step-sections may be the simplest procedure. Obtaining two or three 
tissue levels has been proposed, each consisting of five or more sections.121 Routine staining with haematoxylin 
and eosin are appropriate for diagnosis. [EL5, RG D]. At present special stains, immunohistochemistry, or other 
techniques for diagnostic purposes are not needed routinely. 
This proposal is in agreement with guidelines proposed by the German, Austrian and Swiss Inflammatory Bowel 
Disease Study groups and the British Society of Gastroenterology initiative.116,122-126 The use of multiple biopsies 
from different sites is supported by the expert opinion of clinicians, except for patients presenting with fulminant 
colitis. Fifty-eight percent of the clinicians agree to take 2 samples from one or two regions in fulminant colitis. 
Eight percent do not perform endoscopy in fulminant colitis and 34% would take only one sample. The proposal 
to use multiple biopsies for the diagnosis of Crohn's disease is supported by data from the literature.112,113 For 
fulminant colitis, there are no appropriate data available. 
 
3.2. Diagnostic features 
3.2.1. Combined microscopic features 
ECCO statement 3F 
Focal (discontinuous) chronic (lymphocytes and plasma cells) inflammation and patchy chronic inflammation, 
focal crypt irregularity (discontinuous crypt distortion) and granulomas (not related to crypt injury) are the 
generally accepted microscopic features which allow a diagnosis of Crohn's disease [EL2, RG B]. The same 
features and, in addition, an irregular villous architecture, can be used for analysis of endoscopic biopsy samples 
from the ileum. If the ileitis is in continuity with colitis, the diagnostic value of this feature should be used with 
caution [EL2, RG B]. 
A large variety of microscopic features have been identified which help to establish a diagnosis of Crohn's 
disease, and reported in the literature. They are summarized in Table 3.1. The reproducibility of these features, as 
well as sensitivity and specificity has been studied repeatedly (Section 3.2.5). 
 
3.2.2.  Focal or patchy inflammation 
Focal or patchy chronic inflammation means a variable increase in lamina propria cellularity across the biopsy 
specimen and not confined to the superficial zone. A focal increase implies a normal background cellularity with 
a localised increase in cells. Patchy increase means an abnormal background cellularity with variable intensity. 
Focal or patchy increase should not be confused with the presence of normal lymphoid aggregates. Differences 
in cellularity between multiple biopsy specimens can be assessed with greater reproducibility than variation 
within a single specimen. 
 
3.2.3.  Crypt irregularity 
Crypt irregularity implies crypt abnormalities in >10% of the crypts when focal or patchy inflammation is 
present. Crypt irregularity can be either crypt distortion (non-parallel crypts, variable diameter or cystically 
dilated crypts), crypt branching and crypt shortening.116 The presence of more than two branched crypts in a 
well-orientated biopsy specimen can be regarded as abnormal.116 
 
3.2.4.  Granulomas 
The granuloma in Crohn's disease is defined as a collection of epithelioid histiocytes (monocyte/macrophage 
cells), the outlines of which are often vaguely defined. Multinucleated giant cells are not characteristic and 
necrosis is usually not apparent. Only granulomas in the lamina propria not associated with active crypt injury 
may be regarded as a corroborating feature of Crohn's disease. Granulomas associated with crypt injury are less 
reliable features.127 Non-caseating granulomas, small collections of epithelioid histiocytes and giant cells, or 
isolated giant cells can be observed in infectious colitis (granulomas suggest Mycobacterium sp., Chlamydia sp., 
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Yersinia pseudotuberculosis, and Treponema sp.; microgranulomas suggest Salmonella sp., Campylobacter sp., 
and Yersinia enterocolitica; and giant cells suggest Chlamydia sp.) and must not be regarded as evidence for 
Crohn's disease. In patients living in or originating from areas with a high prevalence of tuberculosis, intestinal 
tuberculosis should be actively excluded in patients with suspected Crohn's disease. This is of particular 
relevance before starting anti TNF therapy. 
 
Table 3.1     Microscopic features used for the diagnosis of Crohn's disease. 
Colon  
Architecture  
Crypt architectural irregularity Focal 
 Diffuse 
Reduced crypt numbers/mucosal atrophy  
Irregular surface  
Chronic inflammation  
Distribution I Focal increase in 
 intensity 
 Patchy increase 
 Diffuse increase 
Distribution II Superficial 
 Transmucosal 
 Basal plasma cells 
Granulomas  
Mucin granulomas  
Polymorph inflammation  
Lamina propria  
Crypt epithelial polymorphs  
 Focal 
 Diffuse 
Crypt abscess  
Polymorph exudates  




Paneth cells distal to hepatic flexure  
Epithelial associated changes  
Increased intraepithelial lymphocytes > 15  
Terminal ileum  
Architecture  
Villus irregularity  
Crypt architecture irregularity  
Epithelial changes  
Pseudopyloric gland metaplasia (ulcer associated cell lineage-UACL) 
Comparison between different segments 
Distribution of inflammation along the colon: gradient from proximal to distal 
Ratio of number of biopsies with focal cell infiltration to number of biopsies 
with mononuclear cell infiltration 
 
3.2.5.  Number of features needed for diagnosis 
The selection of these features is based upon a systematic literature review. They achieve a diagnostic sensitivity 
and specificity of at least 50% and a moderate to good reproducibility (kappa of 0.4 or percentage agreement of 
at least 80%).119,120,128,129 They were presented to a panel of experts and scored according to the quality of the 
study and expert opinion. Focal crypt irregularity scored highest on the evidence of more than one valid study of 
adequate size and from expert opinion; focal or patchy chronic inflammation was validated by evidence from 
single paper and expert opinion. The features were also tested in a workshop, involving non-expert and expert 
pathologists and selected by 50% or more of the pathologists correctly identifying each case.112 The patchy 
nature of the inflammation is only diagnostic in untreated adult patients. Inflammation can become patchy in 
ulcerative colitis under treatment, and young children (age <10 years) with ulcerative colitis may present with 
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discontinuous inflammation.130-135 
The presence of one single feature is not regarded as sufficient for a firm diagnosis. For single or multiple 
endoscopic samples there are no data available as to how many features must be present for a firm diagnosis of 
Crohn's disease. For surgical material, it has been suggested that a diagnosis of Crohn's disease should be made 
when three features are present in the absence of granulomas, or when an epithelioid granuloma is present with 
one other feature provided that specific infections are excluded [EL5, RG D].125 The same definition could be 
proposed for mucosal samples obtained during endoscopy. The following features can be identified in the 
mucosa and thus in endoscopic biopsy samples: granulomas and focal (segmental or discontinuous) crypt 
architectural abnormalities, in conjunction with focal or patchy chronic inflammation (chronic is defined as 
presence of lymphocytes and plasma cells), or mucin preservation at active sites. These are, therefore, potentially 
reliable markers for the diagnosis of Crohn's disease. 
The majority of the expert clinicians (91%) and all pathologists agree that the presence of a granuloma and at 
least one other feature establishes a diagnosis of Crohn's disease. The second feature can be either inflammation 
(focal) or, preferably, architectural abnormalities. A pseudovillous appearance of the colorectal surface is more 
predictive of ulcerative colitis, while focal architectural abnormalities favour Crohn's disease. However, finding 
a granuloma is not always necessary for a diagnosis of Crohn's disease. Additional features which have been 
found to be useful are increased intraepithelial lymphocytes,112 transmucosal inflammation,128 focal chronic 
inflammation without crypt atrophy, focal cryptitis (although reproducibility is poor),116,136 aphthoid ulcers, 
disproportionate submucosal inflammation, nerve fibre hyperplasia137 and proximal location of ulceration and 
architectural distortion. When multiple biopsies are available, ileal involvement and a distribution of the 
inflammation showing a proximal to distal gradient can also be useful. The absence of features that are highly 
suggestive or diagnostic of ulcerative colitis, such as diffuse crypt irregularity; reduced crypt numbers and 
general crypt epithelial polymorphs, can also orient towards a diagnosis of Crohn's disease. 
In difficult cases, gastric biopsies might help establish the diagnosis of Crohn's disease by the presence of 
granulomas or focally-enhanced or focal active gastritis. The latter is characterized by the absence of Heliobacter 
pylori and the presence of a perifoveolar or periglandular cellular infiltrate composed of mononuclear cells 
(CD3+ T cells and CD68+ cells) and granulocytes. Focal gastritis is not exclusive to Crohn's disease [EL4, RG 
C].138-142 
 
3.3. Histology and dysplasia-intraepithelial neoplasia 
ECCO statement 3G 
The microscopic features for the diagnosis and grading of dysplasia-intraepithelial neoplasia of the colon in 
Crohn's disease are the same as those proposed for ulcerative colitis and, similarly, a second opinion is 
recommended for a firm diagnosis [EL2, RG B]. 
ECCO statement 3H 
As for ulcerative colitis, sporadic adenomas may be difficult to distinguish from dysplasia-associated lesions or 
masses (DALM). The distinction is however important, because the management of sporadic adenomas differs 
from that of colitis-associated dysplasia. The patient's age, the site and morphology of the lesion, along with 
biopsies of flat surrounding mucosal, may be helpful in this distinction [EL2, RG B]. 
 
3.3.1.  Number of biopsies 
Patients with extensive Crohn's colitis carry an increased risk of colorectal cancer. Endoscopy with biopsy can be 
used for secondary prevention and the detection of dysplasia (intraepithelial neoplasia) in ulcerative colitis [EL2, 
RG C]. The optimal number of biopsies required for a reliable diagnosis of intraepithelial neoplasia has not been 
established. It has been proposed that 6 to 10 samples from different sites in the colon should be obtained, as 
suggested for ulcerative colitis. The current recommendation is to biopsy the colon at 10 cm intervals. Biopsies 
are labelled separately so that the segment of colon from which the tissue is obtained can be subsequently 
identified. It has been estimated that 33 biopsy specimens are required to give 90% confidence in the detection of 
dysplasia if it is indeed present.143 These studies on ulcerative colitis have not been replicated in Crohn's colitis. 
The focal nature of inflammation in Crohn's colitis, the possibility of strictures and the prevalence of segmental 
resection means that surveillance practice in ulcerative colitis cannot be transferred directly to Crohn's colitis. 
The purpose of this section is not designed to make surveillance recommendations, but to acknowledge that if it 
is performed then the number of biopsies necessary to detect dysplasia is large. The use of targeted biopsies, 
aimed at lesions identified by chromoendoscopy or endomicroscopy, has changed the policy of taking biopsies in 
ulcerative colitis and this policy should also be considered in patients with Crohn's colitis. 
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3.3.2.  Microscopic features 
Microscopic features that are used for a diagnosis of intraepithelial neoplasia include architectural and 
cytological abnormalities. Architectural abnormalities are crowding of glands, thickening of the mucosa, and 
lengthening and distortion of the crypts with excessive budding and increased size. Surface and crypts are lined 
by tall, high columnar cells in which there is some mucus differentiation. Mucin tends to be in columnar cells 
rather than in the usual goblet cells. Nuclear changes are morphologically similar to those seen in tubular 
adenomas: hyperchromatic and enlarged nuclei, with nuclear crowding and frequent overlapping. The nuclei are 
also typically stratified. Mitotic figures may be present in the upper part of the crypt, and even in the surface 
(which is abnormal).144-145 
 
3.3.3. Additional techniques 
The use of additional techniques (including flow cytometry, immunohistochemistry) and the search for markers 
(such as the expression of p53) can be helpful for solving diagnostic problems and to support the diagnosis of 
intraepithelial neoplasia. These techniques, however, identify changes that are not entirely the same as dysplastic 
changes, which represent a complex phenomenon. Therefore, and because of practical availability and costs, the 
simple morphological recognition of dysplasia remains important for the management of the cancer risk in 
Crohn's disease. 
 
3.4.  Surgery and pathology 
ECCO statement 3I 
A surgical sample needs a complete gross examination, carried out in an orderly and systematic manner, 
including photographic documentation, preferably at the time when the specimen is removed [EL5, RG D]. Once 
gross observations are completed, the sample is opened along its longitudinal axis (along the antimesenteric or 
antimesocolic border, except perhaps at the sites of any carcinoma, where it may be preferable to leave that small 
segment unopened during fixation) and specimens for microscopy are collected, including the lymph nodes, 
terminal ileum and appendix [EL2, RG B]. 
ECCO statement 3J 
The optimum number of samples from a colectomy specimen that should be obtained has not been established. 
However, multiple samples will improve the diagnostic yield. It is a mistake to sample only visible lesions. The 
samples can be processed routinely [EL5, RG D]. 
When surgical samples are available, the macroscopic aspects of the condition and the transmural character of 
the disease can be identified and in general many more features can be used for diagnostic purposes.137,146 The 
features are summarized in Tables 3.2 and 3.3. Fat wrapping has a high predictive value for the diagnosis of 
Crohn's disease.115,116 
 
3.5.  Histology and disease activity 
ECCO statement 3K 
The pathology report should give an indication of the activity of the disease. Inactivity in the biopsy may not 
reflect inactivity in the patient [EL5, RG D]. 
Histology is routinely used for the diagnosis of ulcerative colitis (UC) and Crohn's disease (CD). The occurrence 
of healing of mucosal inflammation has already been noted as a feature of resolution in UC. Therefore, biopsies 
are used to discriminate between quiescent disease, inactive disease and different grades of activity in UC. This 
has led to the introduction of scoring systems for the assessment of disease activity in UC and their use in 
clinical drug trials.143 
In contrast with UC, disease activity is not generally assessed by pathologists for CD. This is mainly due to the 
discontinuous character of the disease, inducing sampling error and the fact that the ileum may be the only area 
involved. Sampling error is very important, especially when only rectal biopsies are available. Microscopic 
analysis of multiple samples from different segments of the colon and ileum might provide useful information 
and allow an assessment of disease activity. Arguments in favour come from other diseases such as UC and H. 
pylori-related gastritis and from clinical drug trials. In UC, basal plasmacytosis can also help to predict relapse, 
while adequate control of inflammation seems important for the prevention of the development of cancer,147-152 
but neither have yet been studied in Crohn's disease. The data available on histology and activity for Crohn's 
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disease are limited. Several clinical drug trials have shown that medical treatment can alter the mucosal 
histology, promoting healing and normalisation of the mucosa.151-158 There is, however, no general agreement 
among expert clinicians about the use of microscopy to assess disease activity. If biopsies are used, then multiple 
samples have to be obtained and analysed. The presence of epithelial damage in association with neutrophils is a 
marker of disease activity.149 In Crohn's disease a multivariate logistic regression model showed that severe 
lymphocytic (and eosinophilic) infiltration of the lamina propria, presence of crypt atrophy and absence of 
lymphocytic infiltration of the epithelium are the best variables for predicting uncomplicated disease.159 
 
Table 3.2     Macroscopic features for the diagnosis of Crohn's disease. 
-Ileal disease* 
-Rectum typically spared 




-Skip lesions (segmental disease) 
-Cobblestoning 
-Thickening of the intestinal wall* 
-Strictures 
* Typical discriminating features for a diagnosis of Crohn's disease as opposed to other conditions. 
 
Table 3.3     Microscopic features for the diagnosis of Crohn's disease in surgical specimens. 
-Transmural inflammation 
-Aggregated inflammatory pattern, transmural lymphoid hyperplasia * 
-Submucosal thickening (expansion by fibrosis-fibromuscular obliteration and inflammation) 
-Fissures 
-Sarcoid granuloma (including in lymph nodes)* 
-Abnormalities of the enteric nervous system (submucosal nerve fibre hyperplasia and ganglionitis) * 
-Relatively unchanged epithelia-mucin preservation (goblet cells often normal) 
* Typical discriminating features for a diagnosis of Crohn's disease as opposed to other conditions. 
 
4. Classification of Crohn's disease 
Principal changes with respect to the 2004 ECCO guidelines. 
•  The use of the Montréal classification of clinical CD phenotypes is advocated [statement 4A]. 
•  The course of CD may be predicted by clinical factors at diagnosis [statement 4B]. 
Disease classification is an important step to provide appropriate tools that enable us to dissect differences in the 
features and behaviour of Crohn's disease. Several ways of classifying CD have been used in the past. CD has 
been classified by disease phenotype (Rome or Vienna classification, modified in Montréal), by disease activity 
(mostly according to the Crohn's Disease Activity Index, CDAI), and by response to therapy (mainly steroids: 
'steroid-resistant' or 'steroid-dependent', above). Since there is a strong trend toward the prescription of earlier 
and more aggressive maintenance therapies, some efforts are currently made to predict at diagnosis the 
subsequent phenotype of the disease, in order to adapt the level of the therapy to the severity of the disease. 
Some rough clinical predictors have been recently identified. In addition, there is an intense research devoted to 
the identification of genetic and serological predictors, so that it may hopefully be possible in the next few years 
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4.1. General recommendations 
ECCO statement 4A 
The use of Montréal classification of Crohn's disease is advocated. No evidence-based recommendation can be 
made at this time to implement the routine clinical use of genetic tests or serological markers to classify Crohn's 
disease. 
ECCO statement 4B 
The course of Crohn's disease may be predicted by clinical factors at diagnosis (including young age, ileocolonic 
location and perianal disease) which should be taken into account when determining the initial therapeutic 
strategy [EL2b RG C]. 
ECCO Statement 4C 
Serum levels of CRP are useful for assessing a patient's risk of relapse [EL2b, RG B]. High CRP levels are 
indicative of active disease [EL2a, RG B] or a bacterial complication [EL3, RG C]. CRP levels can be used to 
guide therapy and follow up [EL2a, RG B]. 
 
4.2. Specific components 
4.2.1.  Montréal phenotype classification 
The Montréal revision (2005)160,161 of the Vienna classification162 is now regarded as the international standard 
of phenotype subtyping in Crohn's disease. Two major adjustments have been made in the Montréal 
classification. First, regarding disease location, the upper GI location (L4) is now added to the three major ones 
(terminal ileum (L1), colon (L2) and ileocolon (L3)) instead of being considered a mutually exclusive category. 
Second, regarding disease behaviour categories (non-stricturing non-penetrating (B1), structuring (B2) and 
penetrating (B3)), perianal fistulae and abscesses are no longer included in the penetrating phenotype that is now 
defined as "the occurrence of intra-abdominal fistulae, inflammatory masses and/or abscesses at any time in the 
course of the disease". The occurrence of perianal fistulae and abscesses is now indicated by a 'p' (for perianal) 
appended to B1, B2 or B3. It is established that in adult patients, location subtyping remains stable over time 
after diagnosis whereas the distribution of behaviour phenotype in patient populations changes continuously over 
time, with an increasing number of patients progressing from non-penetrating, non-structuring disease, to 
structuring or penetrating disease.163,164 The superiority of Montréal classification over the Vienna classification 
in detecting early changes in Crohn's disease behaviour phenotype, associated with the need for subsequent 
major surgery, has been validated in a non-white population.165 
 
4.2.2.  Clinical predictors at diagnosis of subsequent phenotype 
Increasing evidence suggests that early intensive therapy in Crohn's disease with immunomodulators and/or 
biologies is associated with an increased probability of mucosal healing and early sustained remission without 
steroids.166,167 Given the risks of immunosuppressive therapy, only patients who would have experienced 
spontaneously a disabling and/or severe disease on a mid-term basis after diagnosis should be considered for 
early intensive therapy. There is no consensual definition of a disabling and/or severe disease but all or some of 
the following severity factors are usually used for defining a severe evolution within the first years of the 
disease: sustained disabling symptoms and impaired quality of life, repeated flare-ups with or without 
hospitalisation, development of irreversible penetrating and/or stricturing lesions, need for repeated courses of 
steroids and need for surgery. Using various combinations of these criteria, concordant data from three 
independent patient cohorts (two from referral centres168,169 and one population-based170) suggest that the 
presence of perianal lesions and/or ileocolonic location and/or young age at diagnosis together with the need for 
treating the first flare with steroids is associated with a high risk of disabling disease within the 5-year period 
after diagnosis. When two or more predictors are present in an individual patient, early treatment with 
thiopurines and /or biologics should be considered. (For an extensive review and guidelines on initiating 
immunosuppressive and biological therapy see Section 5.4 in Current Management). 
 
4.2.3.  Classification by serum CRP and faecal markers 
It holds true that serum levels of CRP are useful for assessing a patient's risk of relapse [EL2b, RG B] and that 
high CRP levels are indicative of active disease [EL2a, RG B] or a bacterial complication [EL3, RG C]. A recent 
study suggests that high-sensitivity CRP could have a stronger association with disease activity171 than that 
previously reported with standard CRP but these data must be reproduced before recommending the routine 
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clinical use of high-sensitivity, instead of standard, CRP. 
Growing evidence suggests that mucosal healing is a surrogate marker of sustained controlled Crohn's 
disease.167,172 Endoscopy is still considered the standard for evaluation of mucosal healing but is invasive and 
costly. The faecal concentration of calprotectin and lactoferrin reflects the migration of neutrophils through the 
inflamed bowel wall to the mucosa. Both calprotectin and lactoferrin are stable, degradation-resistant proteins 
that can be easily measured in stools using enzyme-linked immunosorbent assay. Increased faecal levels of 
calprotectin and lactoferrin reflect intestinal inflammation of any cause, and in Crohn's disease they have a >90% 
positive predictive value for endoscopically active disease [EL2b, RGB].173 As for serum CRP, the limit of the 
accuracy of faecal markers is that some patients have endoscopically active disease and faecal protein levels 
within the normal range, more often in the case of ileal than colonic disease.173,174 However, the 60 to 70% 
sensitivity of raised faecal markers for predicting concurrent endoscopically active disease is superior to that of 
serum CRP and clearly superior to CDAI.173 In summary, faecal levels of calprotectin or lactoferrin are emerging 
as a surrogate marker of mucosal healing, but the predictive value of uniform thresholds at an individual level 
has not been clearly demonstrated. 
 
4.2.4.  Correlation between genetic and serological markers and phenotype 
Genome wide association defines more than 30 distinct susceptibility loci for Crohn's disease.175 However, none 
of them is associated with an individual risk for developing the disease high enough to justify the routine use of 
genetic tests. Regarding genotype-phenotype correlations, only NOD2 variants and 5q31 susceptibility haplotype 
have been reproducibly shown to be associated with ileal location and penetrating perianal disease, 
respectively.176,177 In contrast, recent concordant data suggest a significant relationship between the severity of 
Crohn's disease and the presence and levels of serological markers. Using slightly different panels of serological 
markers, the number and magnitude of immune responses to different microbial antigens were shown to be 
associated with the severity of the disease, characterized by the occurrence of stricturing/penetrating lesions and 
the need for surgery.176 However, at diagnosis, the positive predictive value of serological markers for 
subsequent disease course appears to be limited.176 
 
4.2.5. Need for a composite predictive index at diagnosis 
Given the complex benefit-risk balance of early aggressive therapeutic strategies using immunomodulators and 
biologics in CD, there is an increasing need for identifying at diagnosis patients who are likely to develop severe 
or complicated disease. Simple clinical predictors have been identified, but their individual accuracy remains 
limited. Genetic factors and serological markers of immune reactivity, considered alone or in combination, have 
been so far unhelpful in predicting the future course of CD at diagnosis. This is why further studies are needed to 
assess collectively all potential predictors in large, phenotypically well-defined cohorts, in order to build an 
accurate composite predictor index. 
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